Iterum Therapeutics PLC (NAS:ITRM)

$ 1.465 0.035 (2.45%) Market Cap: 24.25 Mil Enterprise Value: 25.64 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Q1 2024 Iterum Therapeutics PLC Earnings Call Transcript
May 13, 2024

$1.52 (-1.94%)

Earnings
Q4 2023 Iterum Therapeutics PLC Earnings Call Transcript
Mar 28, 2024

$1.54 (-3.14%)

Earnings
Iterum Therapeutics PLC Phase 3 Topline Data Conference Call Transcript
Jan 30, 2024
Q3 2023 Iterum Therapeutics PLC Earnings Call Transcript
Nov 14, 2023

$0.79 (+2.61%)

Earnings
Q2 2023 Iterum Therapeutics PLC Earnings Call Transcript
Aug 11, 2023

$1.09 (+7.92%)

Earnings
Q4 2022 Iterum Therapeutics PLC Earnings Call Transcript
Mar 16, 2023

$1.15 (+15.00%)

Earnings
Iterum Therapeutics PLC at SRAX Sequire Biotechnology Conference (Virtual) Transcript
Feb 02, 2023
Q3 2022 Iterum Therapeutics PLC Earnings Call Transcript
Nov 10, 2022

$1.43 (+0.35%)

Earnings
Q4 2021 Iterum Therapeutics PLC Earnings Call Transcript
Mar 28, 2022

$5.76 (-14.27%)

Earnings
Q3 2021 Iterum Therapeutics PLC Earnings Call Transcript
Nov 12, 2021

$8.52 (-6.73%)

Earnings
Q2 2021 Iterum Therapeutics PLC Earnings Call Transcript
Aug 13, 2021

$10.46 (-4.45%)

Earnings
Q1 2021 Iterum Therapeutics PLC Earnings Call Transcript
May 14, 2021

$15.75 (+8.25%)

Earnings

Q2 2021 Iterum Therapeutics PLC Earnings Call Transcript

Aug 13, 2021 / 12:30PM GMT

Release Date Price: $10.46 (-4.45%)

Transcript 10-Q8-K

Operator

Hello, and welcome to Iterum Therapeutics Q2 Financial Results Conference Call. (Operator Instructions)

I now have the pleasure of handing over to Louise Barrett, Senior Vice President of Legal Affairs.

Louise Barrett

Iterum Therapeutics plc - SVP of Legal Affairs & Secretary

Thank you, Hannah. Good morning, and welcome to Interim Therapeutics Second Quarter 2021 Financial Results and Business Update Conference Call. A press release with the company's second quarter results was issued earlier this morning and can be found on our website.

We are joined this morning by Corey Fishman, CEO; and Judy Matthews, CFO. Corey will provide some opening remarks. Judy will provide details on our financial results, and then we'll open the floor for Q&A.

Before we begin, I'd like to remind you that this call will contain forward-looking statements concerning our plans, strategies and prospects for our business, including with respect to planned interactions and communications with the FDA following receipt of the Complete Response Letter

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.